Last edition
News about "Daraxonrasib"
US FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The US Food and Drug Administration (FDA) has approved the first targeted therapy for metastatic pancreatic cancer, advancing an innovative treatment option for patients with limited choices.
Daraxonrasib | 27/08/2026 | By News Bureau
EMA Fast-Tracks Review of New Metastatic Pancreatic Cancer Drug
The European Medicines Agency (EMA) has initiated a phased review of a new medicine for metastatic pancreatic cancer, accelerating its assessment to address a significant unmet medical need.
Daraxonrasib | 09/07/2026 | By News Bureau | 116
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib
Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.
Daraxonrasib | 04/07/2026 | By News Bureau | 162
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
Daraxonrasib | 04/05/2026 | By News Bureau | 537
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy